These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26303700)

  • 1. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
    Peters ME; Vaidya V; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Avramopoulos D;
    J Geriatr Psychiatry Neurol; 2016 Mar; 29(2):59-64. PubMed ID: 26303700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
    Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
    JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
    Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
    Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
    Ehrhardt S; Porsteinsson AP; Munro CA; Rosenberg PB; Pollock BG; Devanand DP; Mintzer J; Rajji TK; Ismail Z; Schneider LS; Baksh SN; Drye LT; Avramopoulos D; Shade DM; Lyketsos CG;
    Alzheimers Dement; 2019 Nov; 15(11):1427-1436. PubMed ID: 31587995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Citalopram for agitation in Alzheimer's disease: design and methods.
    Drye LT; Ismail Z; Porsteinsson AP; Rosenberg PB; Weintraub D; Marano C; Pelton G; Frangakis C; Rabins PV; Munro CA; Meinert CL; Devanand DP; Yesavage J; Mintzer JE; Schneider LS; Pollock BG; Lyketsos CG;
    Alzheimers Dement; 2012; 8(2):121-30. PubMed ID: 22301195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.
    Weintraub D; Drye LT; Porsteinsson AP; Rosenberg PB; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Yesavage J; Lyketsos CG;
    Am J Geriatr Psychiatry; 2015 Nov; 23(11):1127-33. PubMed ID: 26238225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sertraline for the treatment of depression in Alzheimer disease: genetic influences.
    Peters ME; Vaidya V; Drye LT; Rosenberg PB; Martin BK; Porsteinsson AP; Frangakis CE; Mintzer J; Weintraub D; Schneider LS; Rabins PV; Munro CA; Meinert CL; Lyketsos CG; Avramopoulos D;
    J Geriatr Psychiatry Neurol; 2011 Dec; 24(4):222-8. PubMed ID: 22228829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.
    Ho T; Pollock BG; Mulsant BH; Schantz O; Devanand DP; Mintzer JE; Porsteinsson AP; Schneider LS; Weintraub D; Yesavage J; Drye LT; Munro CA; Shade DM; Lyketsos C; Bies R
    Br J Clin Pharmacol; 2016 Sep; 82(3):784-92. PubMed ID: 27145364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressants for agitation and psychosis in dementia.
    Seitz DP; Adunuri N; Gill SS; Gruneir A; Herrmann N; Rochon P
    Cochrane Database Syst Rev; 2011 Feb; (2):CD008191. PubMed ID: 21328305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
    Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
    Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Principal components analysis of agitation outcomes in Alzheimer's disease.
    Yesavage JA; Taylor JL; Friedman L; Rosenberg PB; Lazzeroni LC; Leoutsakos JS; Kinoshita LM; Perlow MJ; Munro CA; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
    J Psychiatr Res; 2016 Aug; 79():4-7. PubMed ID: 27115509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
    Viscogliosi G; Chiriac IM; Ettorre E
    J Am Med Dir Assoc; 2017 Sep; 18(9):799-802. PubMed ID: 28739492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of citalopram in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Keltz MA; Smith JS
    Neurodegener Dis Manag; 2014; 4(5):345-9. PubMed ID: 25405648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.
    Newell J; Yesavage JA; Taylor JL; Kraemer HC; Munro CA; Friedman L; Rosenberg PB; Madore M; Chao SZ; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
    J Psychiatr Res; 2016 Mar; 74():17-21. PubMed ID: 26736036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
    Drye LT; Spragg D; Devanand DP; Frangakis C; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
    PLoS One; 2014; 9(6):e98426. PubMed ID: 24914549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.
    Tao Y; Peters ME; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Munro CA
    Am J Alzheimers Dis Other Demen; 2018 Nov; 33(7):450-457. PubMed ID: 29969907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram.
    Aga VM
    Am J Geriatr Psychiatry; 2019 Oct; 27(10):1099-1107. PubMed ID: 31288974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
    Pollock BG; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Huber KA
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):942-52. PubMed ID: 17846102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder.
    Jarčušková D; Tkáč I; Hlaváčová N; Yaluri AS; Kozárová M; Habalová V; Klimčáková L; Židzik J; Javorský M; Bednářová A
    BMC Psychiatry; 2024 Oct; 24(1):690. PubMed ID: 39407134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.
    Garfield LD; Dixon D; Nowotny P; Lotrich FE; Pollock BG; Kristjansson SD; Doré PM; Lenze EJ
    Am J Geriatr Psychiatry; 2014 Oct; 22(10):971-9. PubMed ID: 24021217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.